ArticleBreast cancer research : BCR2009

QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model.

Jessica Kalra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.